FDA lifts clin­i­cal hold on Sarep­ta's Duchenne MD gene ther­a­py, clear­ing the way to a quick launch of a piv­otal tri­al

In a swift turn­around, Sarep­ta an­nounced that it has cleared the FDA’s con­cerns about its gene ther­a­py pro­gram for Duchenne mus­cu­lar dy­s­tro­phy, con­vinc­ing reg­u­la­tors to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER